Congress is considering changes that would significantly alter how Pharmacy Benefit Managers (PBMs) are compensated in commercial insurance. See our report and full analysis.
How a biotech company equipped HCPs to navigate acquisition, coding, and coverage for a dual-therapy regimen.
How program management and strategic alignment prepared a biopharma company for NDA submission and launch.
How a manufacturer integrated imaging requirements into its access and patient support strategy.
How payer research helped refine value messaging, pricing strategy, and evidence plans.
How a pharmaceutical company built a compliant, scalable 340B contract pharmacy program.
Real-world evidence is no longer just a regulatory checkbox—it’s a strategic driver of pricing, access, and payer engagement. Discover how leading life sciences teams are embedding RWE earlier to shape reimbursement strategy, optimize launch planning, and unlock value-based contracts.
As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.
See how a smarter coding strategy helped a medical device company strengthen payer alignment and accelerate access.
Magnolia Market Access released its fifth iteration of the IRA Payer Insights Survey in the summer of 2025 to understand how the IRA will affect the Medicare Part D program, including beneficiary premiums, formulary coverage, and contract negotiations for manufacturers and payers.